non-invasive sagging skin treatment glp-1 no downtime + EMFACE before & after ✨ Weight loss with GLP-1 medications can be life-changing… but it can also come with unexpected facial changes like volume loss, laxity, and that “tired” Demystifying “GLP1 Face” | Impressions

Studies with sotagliflozin did not include patients with an eGFR less than 25 or on dialysis and in these studies, sotagliflozin was discontinued if eGFR fell below 15 or chronic dialysis was initiated

Lower monthly costs The math is straightforward

Retrieved from Nollet, M., Wisden, W., Franks, N

In one analysis, individuals with obesity treated with GLP-1s incurred significantly higher annual healthcare costs than individuals with obesity without GLP-1 use ($7000 higher in the first year, and $4200 higher in the second year)

The relationship remained consistent after adjustment for study duration, baseline body mass index, sex distribution and diabetes status, at 0.36 millimetres of mercury per one per cent weight loss

Although the ELIXA studythe only CVD outcome trial of GLP-1 RAs published to datereported a neutral cardiovascular effect of lixisenatide, the potential cardiovascular benefits of GLP-1 RAs should not be overlooked, because high-risk subjects with established CVD were recruited in this study to delineate its cardiovascular safety within a short-term period